Literature DB >> 17222085

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline.

G Waldemar1, B Dubois, M Emre, J Georges, I G McKeith, M Rossor, P Scheltens, P Tariska, B Winblad.   

Abstract

The aim of this international guideline on dementia was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with dementia. It covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician. The main focus is Alzheimer's disease, but many of the recommendations apply to dementia disorders in general. The task force working group considered and classified evidence from original research reports, meta-analysis, and systematic reviews, published before January 2006. The evidence was classified and consensus recommendations graded according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. The recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, genetic testing, tissue biopsy, disclosure of diagnosis, treatment of Alzheimer's disease, and counselling and support for caregivers were all revised when compared with the previous EFNS guideline. New recommendations were added for the treatment of vascular dementia, Parkinson's disease dementia, and dementia with Lewy bodies, for monitoring treatment, for treatment of behavioural and psychological symptoms in dementia, and for legal issues. The specialist physician plays an important role together with primary care physicians in the multidisciplinary dementia teams, which have been established throughout Europe. This guideline may contribute to the definition of the role of the specialist physician in providing dementia health care.

Entities:  

Mesh:

Year:  2007        PMID: 17222085     DOI: 10.1111/j.1468-1331.2006.01605.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  133 in total

1.  BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

Authors:  Caterina Chianella; Daniela Gragnaniello; Pierpaolo Maisano Delser; Maria Francesca Visentini; Elisabetta Sette; Maria Rosaria Tola; Guido Barbujani; Silvia Fuselli
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

2.  Alzheimer's therapies.

Authors:  Elisa F Cascade; Amir H Kalali; Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2007-08

3.  CSF metabolites in the differential diagnosis of Alzheimer's disease from frontal variant of frontotemporal dementia.

Authors:  Francesca de Rino; Filippo Martinelli-Boneschi; Francesca Caso; Marta Zuffi; Matteo Zabeo; Gabriella Passerini; Giancarlo Comi; Giuseppe Magnani; Massimo Franceschi
Journal:  Neurol Sci       Date:  2011-11-29       Impact factor: 3.307

4.  Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Authors:  Edeltraut Kröger; Rob van Marum; Patrick Souverein; Toine Egberts
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

5.  Initial screening of patients for Alzheimer's disease and minimal cognitive impairment.

Authors:  Edmund Howe
Journal:  Psychiatry (Edgmont)       Date:  2007-07

Review 6.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 7.  FDG-PET for early assessment of Alzheimer's disease: isn't the evidence base large enough?

Authors:  Giovanni Lucignani; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

Review 8.  DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders.

Authors:  Hans-Jürgen Möller; Borwin Bandelow; Michael Bauer; Harald Hampel; Sabine C Herpertz; Michael Soyka; Utako B Barnikol; Simone Lista; Emanuel Severus; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-26       Impact factor: 5.270

9.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

10.  Management of Dementia and Depression Utilizing In- Home Passive Sensor Data.

Authors:  Colleen Galambos; Marjorie Skubic; Shaung Wang; Marilyn Rantz
Journal:  Gerontechnology       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.